Abbott Laboratories, commonly known as Abbott, is a leading global healthcare company headquartered in the United States. Founded in 1888, Abbott has established a strong presence in various operational regions, including North America, Europe, and Asia. The company operates primarily in the medical devices, diagnostics, nutrition, and pharmaceuticals sectors. Abbott is renowned for its innovative products, such as the FreeStyle Libre glucose monitoring system and Similac infant formula, which set industry standards for quality and effectiveness. With a commitment to advancing health and well-being, Abbott has achieved significant milestones, including the rapid development of COVID-19 testing solutions. As a market leader, Abbott consistently ranks among the top healthcare companies worldwide, recognised for its dedication to research and development, and its ability to deliver cutting-edge solutions that improve patient outcomes.
How does Abbott's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Abbott's score of 62 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Abbott Laboratories reported significant carbon emissions, totalling approximately 1,000,000,000 kg CO2e globally. This figure includes 730,000,000 kg CO2e from Scope 1 emissions and 640,000,000 kg CO2e from Scope 2 emissions. The company has set ambitious targets to reduce its absolute Scope 1 and 2 emissions by 30% by 2030, using 2018 as the baseline year. This commitment aligns with the Science Based Targets initiative (SBTi) and aims to keep global warming well below 2°C. Abbott's emissions data also highlights regional contributions, with the US alone accounting for approximately 411,000,000 kg CO2e in 2023, comprising 207,000,000 kg CO2e from Scope 1 and 204,000,000 kg CO2e from Scope 2. Other regions, such as Singapore and India, also contribute significantly to the overall emissions. The company has made strides in its sustainability efforts, having previously achieved a 43% reduction in Scope 1 and 2 emissions compared to 2010 levels by 2019, surpassing its 40% reduction target set for 2020. Abbott is committed to further enhancing its sustainability initiatives, including operational energy efficiency, renewable energy purchases, and electrification of processes. Abbott Laboratories is also dedicated to achieving net-zero emissions by 2050, with interim goals to reduce emissions across all scopes. The company’s comprehensive approach to sustainability reflects its commitment to addressing climate change and reducing its environmental impact.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 620,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000 | 0,000,000 |
Scope 2 | 648,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | 000,000,000 | - | - | - | - | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abbott is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.